Search

Your search keyword '"Betteridge, N."' showing total 5 results
Start Over Author "Betteridge, N." Topic arthritis
5 results on '"Betteridge, N."'

1. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis.

Author

Boonen A, Putrik P, Marques ML, Alunno A, Abasolo L, Beaton D, Betteridge N, Bjørk M, Boers M, Boteva B, Fautrel B, Guillemin F, Mateus EF, Nikiphorou E, Péntek M, Pimentel Santos F, Severens JL, Verstappen SMM, Walker-Bone K, Wallman JK, Ter Wee MM, Westhovens R, and Ramiro S

Subjects
Advisory Committees, Data Analysis, Europe, Guidelines as Topic, Humans, Research Design, Research Report, Societies, Medical, Arthritis, Employment, Outcome Assessment, Health Care, Work, Work Engagement
Abstract

Background: Clinical studies with work participation (WP) as an outcome domain pose particular methodological challenges that hamper interpretation, comparison between studies and meta-analyses., Objectives: To develop Points to Consider (PtC) for design, analysis and reporting of studies of patients with inflammatory arthritis that include WP as a primary or secondary outcome domain., Methods: The EULAR Standardised Operating Procedures were followed. A multidisciplinary taskforce with 22 experts including patients with rheumatic diseases, from 10 EULAR countries and Canada, identified methodologic areas of concern. Two systematic literature reviews (SLR) appraised the methodology across these areas. In parallel, two surveys among professional societies and experts outside the taskforce sought for additional methodological areas or existing conducting/reporting recommendations. The taskforce formulated the PtC after presentation of the SLRs and survey results, and discussion. Consensus was obtained through informal voting, with levels of agreement obtained anonymously., Results: Two overarching principles and nine PtC were formulated. The taskforce recommends to align the work-related study objective to the design, duration, and outcome domains/measurement instruments of the study (PtC: 1-3); to identify contextual factors upfront and account for them in analyses (PtC: 4); to account for interdependence of different work outcome domains and for changes in work status over time (PtC: 5-7); to present results as means as well as proportions of patients reaching predefined meaningful categories (PtC: 8) and to explicitly report volumes of productivity loss when costs are an outcome (PtC:9)., Conclusion: Adherence to these EULAR PtC will improve the methodological quality of studies evaluating WP., Competing Interests: Competing interests: AB: research grants from Abbvie and Celgene and honoraria for consultancy or speakers honoraria from UCB, Biogen, Sandoz, Eli Lilly and Galapagos (all to her department); EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, AbbVie and Lilly; FPS: research grant from AbbVie, Novartis; consultancy or speaking fees: AbbVie, Angelini, AstraZeneca, Biogen, Eli Lilly, Laboratórios Vitória, MSD, Novartis, Tecnimed, UCB; SR: research grant from MSD; consultancy or speaking fees: AbbVie, Eli Lilly, MSD, Novartis, Sanofi, UCB; JKW: consultancy fees from Celgene, Eli Lilly, Novartis; RW: consultancy and speakers bureau Celltrion and Galapagos/Gilead., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2021
Full Text
View/download PDF

2. Bone and joint diseases around the world. Arthritis--the greatest health, disability, and civil rights challenge: a UK and international perspective.

Author

Betteridge N

Subjects
Civil Rights legislation & jurisprudence, Disabled Persons legislation & jurisprudence, Global Health, Humans, Prejudice, Social Support, United Kingdom, Arthritis psychology, Arthritis rehabilitation, Disability Evaluation, Disabled Persons education, Disabled Persons psychology, Patient Advocacy standards, Patient Advocacy trends
Abstract

The Bone and Joint Decade provides the opportunity for arthritis to be put firmly on political agendas worldwide. Greater political priority is crucial for everybody with arthritis, no matter where they live. People are "patients" for part of their lives, and people all the time, bringing to attention the need to address issues such as social exclusion, access to services, and negative attitudes and practices in society. The term "disability" is not synonymous with "inability," and should be embraced by people with arthritis. As a concept the term can be empowering to individuals, bonding those who face similar problems, including social exclusion and discrimination. When it is stripped of negative connotations, disability can also offer a positive identity. In the UK, the Disability Discrimination Act 1995 was the product of 25 years of campaigning by people who strongly believed that such discrimination should be illegal. The Act is not perfect and important parts have still to be implemented, but it exists as a resource for people with arthritis who may face discrimination. Only a minority of nations have disability discrimination legislation. Law alone will not end discrimination. If people with arthritis do not identify with being disabled then many people who meet the legal definition will continue to face unnecessary discrimination daily. A moral responsibility exists to help make the term one that attracts rather than deters those whom we seek to represent.

Published
2003

3. Consensus statement on the use of rituximab in patients with rheumatoid arthritis

Author

Smolen, J. S., Keystone, E. C., Emery, P., Breedveld, F. C., Betteridge, N., Burmester, G. R., Dougados, M., Ferraccioli, G., Jaeger, U., Klareskog, L., Kvien, T. K., Martin Mola, E., Pavelka, K., Carbonell, Jordi, Combe, Bernard, Cutolo, Maurizio, Dörner, Thomas, Gause, Angela, Gomez Reino, Juan, Fernandes, Carlos Gonzales, Isaacs, John D., Marenco, José Luis, Mariette, Xavier, Matucci Cerinic, Marco, Montecucco, Carlo Maurizio, Nüßlein, Hubert, Østergaard, Mikkel, Pascual, Eliseo, Van Riel, Piet, Rubbert, Andrea, Sanmarti, Raimon, Sekanecz, Zoltan, Tak, Paul Peter, Tony, Hans Peter, Valesini, Guido, VALENTINI, Gabriele, Smolen, J. S., Keystone, E. C., Emery, P., Breedveld, F. C., Betteridge, N., Burmester, G. R., Dougados, M., Ferraccioli, G., Jaeger, U., Klareskog, L., Kvien, T. K., Martin Mola, E., Pavelka, K., Carbonell, Jordi, Combe, Bernard, Cutolo, Maurizio, Dörner, Thoma, Gause, Angela, Gomez Reino, Juan, Fernandes, Carlos Gonzale, Isaacs, John D., Marenco, José Lui, Mariette, Xavier, Matucci Cerinic, Marco, Montecucco, Carlo Maurizio, Nüßlein, Hubert, Østergaard, Mikkel, Pascual, Eliseo, Van Riel, Piet, Rubbert, Andrea, Sanmarti, Raimon, Sekanecz, Zoltan, Tak, Paul Peter, Tony, Hans Peter, Valentini, Gabriele, and Valesini, Guido

Subjects
musculoskeletal diseases, medicine.medical_specialty, Statement (logic), Immunology, MEDLINE, Arthritis, Review, General Biochemistry, Genetics and Molecular Biology, Drug Administration Schedule, Arthritis, Rheumatoid, Antibodies, Monoclonal, Murine-Derived, Rheumatology, Internal medicine, medicine, Immunology and Allergy, Humans, Intensive care medicine, business.industry, Patient Selection, Antirheumatic Agent, Antibodies, Monoclonal, medicine.disease, Clinical trial, Antirheumatic Agents, Rheumatoid arthritis, Physical therapy, Rituximab, business, medicine.drug, Human
Abstract

A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.

Published
2006

4. Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools

Author

Burmester, GR, Álvaro-Gracia, JM, Betteridge, N, Calvo Alén, J, Combe, B, Durez, P, Fautrel, B, Ferreira, RJO, Gabay, C, Iagnocco, A, Montecucco, C, Østergaard, M, Ramiro, S, Rubbert-Roth, A, Stamm, T, Szekanecz, Z, Taylor, PC, Van de Laar, M, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Humboldt-Universität zu Berlin, Hospital General Universitario 'Gregorio Marañón' [Madrid], Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Hospital Universitario de Araba, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain = Catholic University of Louvain (UCL), Cliniques Universitaires Saint-Luc [Bruxelles], Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centro Hospitalar e Universitário [Coimbra], University of Geneva [Switzerland], Università degli studi di Torino (UNITO), Fondazione IRCCS Policlinico San Matteo [Pavia], Università di Pavia, Rigshospitalet [Copenhagen], Copenhagen University Hospital, University of Copenhagen = Københavns Universitet (KU), Leiden University Medical Center (LUMC), Zuyderland Hospital [Heerlen, The Netherlands], Brustzentrum Kantonsspital St. Gallen, Medizinische Universität Wien = Medical University of Vienna, University of Debrecen, University of Oxford [Oxford], University of Twente [Netherlands], Psychology, Health & Technology, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, and UCL - (SLuc) Service de rhumatologie

Subjects
ddc:616, MESH: Arthritis, Rheumatoid, MESH: Humans, Arthritis, Rheumatoid/diagnosis/therapy, Europe, Humans, Surveys and Questionnaires, Arthritis, Rheumatoid, Rheumatology, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Rheumatoid, MESH: Rheumatology, MESH: Europe, MESH: Surveys and Questionnaires
Abstract

OBJECTIVES: Despite availability of efficacious treatments, unmet needs still exist, preventing optimal and comprehensive management of rheumatoid arthritis (RA). Evolving the management of RA (eRA) is a European-wide educational initiative aiming to support improved patient care through practical and educational tools addressing specific unmet needs. METHODS: A multidisciplinary Steering Committee (17 members, 12 countries) identified unmet needs within the management of RA and prioritised those with the greatest impact on patient outcomes. Practical educational tools addressing priority needs were then developed for dissemination and implementation by the rheumatology community across Europe. RESULTS: Five areas of priority need were identified: increasing early recognition of RA and treatment initiation; treating RA to target; optimal, holistic approach to selection of treatment strategy, including shared decision-making; improving identification and management of comorbidities; and non-pharmacological patient management. A suite of 14 eRA tools included educational slides, best-practice guidance, self‑assessment questionnaires, clinical checklists, a multidisciplinary team training exercise, an interactive patient infographic, and case scenarios. By April 2020, rheumatology professionals in 17 countries had been actively engaged in the eRA programme; in 11 countries, eRA tools were selected by national leaders in rheumatology and translated for local dissemination. A web platform, with country-specific pages, was developed to support access to the translated tools (https://www.evolvingthemanagementofra.com/). CONCLUSIONS: The eRA programme supports comprehensive management of RA across Europe through development and dissemination of practical educational tools. The eRA tools address priority needs and are available free of charge to the rheumatology community.

5. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Author

Mikkel Østergaard, Andrea Rubbert-Roth, Bernard Combe, Ferdinand C. Breedveld, Miho Murakami, Michael Trauner, Marieke Scholte-Voshaar, Angel Lanas, Maarten de Wit, Maurizio Cutolo, Gerd R Burmester, Paul Emery, Gabriele Valentini, Juan J. Gomez-Reino, Kevin L. Winthrop, Tore K Kvien, Gianfranco Ferraccioli, Karel Pavelka, Yoshiya Tanaka, Neil Betteridge, Norihiro Nishimoto, Naveed Sattar, Carlomaurizio Montecucco, Ernest Choy, Maxime Dougados, Winfried Graninger, Clifton O. Bingham, Graeme Jones, Désirée van der Heijde, Cem Gabay, Monika Schoels, Josef S Smolen, Allan Gibofsky, Emilio Martín-Mola, Vivian P. Bykerk, Smolen, J, Schoels, Mm, Nishimoto, N, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, G, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Betteridge, N, Bingham C., 3rd, Bykerk, V, Choy, Eh, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert Roth, A, Sattar, N, Scholte Voshaar, M, Tanaka, Y, Trauner, M, Valentini, Gabriele, Winthrop, Kl, de Wit, M, van der Heijde, D., Ethics, Law & Medical humanities, and CCA - Innovative therapy

Subjects
musculoskeletal diseases, Settore MED/16 - REUMATOLOGIA, Immunology, MEDLINE, Arthritis, Rheumatoid Arthritis, DMARDs (biologic), Bioinformatics, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, chemistry.chemical_compound, Tocilizumab, Rheumatology, medicine, Immunology and Allergy, Humans, Inflammation/drug therapy/immunology, Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects, Interleukin 6, skin and connective tissue diseases, ddc:616, Inflammation, biology, business.industry, Interleukin-6, Consensus Statement, medicine.disease, Connective tissue disease, Receptors, Interleukin-6, R1, Antirheumatic Agents/administration & dosage/adverse effects, Antirheumatic Agents, Arthritis, Rheumatoid/drug therapy/immunology, Treatment, chemistry, Interleukin-6/antagonists & inhibitors, Rheumatoid arthritis, Interleukin-6 receptor, Receptors, Interleukin-6/antagonists & inhibitors, biology.protein, Drug Monitoring, business, Drug Monitoring/methods
Abstract

Background: Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.\ud \ud Methods: Preparation of this document involved international experts in RA treatment and RA patients. A systematic literature search was performed that focused on TCZ and other IL6-pathway inhibitors in RA and other diseases. Subsequently, incorporating available published evidence and expert opinion, the steering committee and a broader expert committee (both including RA patients) formulated the current consensus statement.\ud \ud Results: The consensus statement covers use of TCZ as combination- or monotherapy in various RA populations and includes clinical, functional and structural aspects. The statement also addresses the second approved indication in Europe JIA and non-approved indications. Also early phase trials involving additional agents that target the IL-6 receptor or IL-6 were evaluated. Safety concerns, including haematological, hepatic and metabolic issues as well as infections, are addressed likewise.\ud \ud Conclusions: The consensus statement identifies points to consider when using TCZ, regarding indications, contraindications, screening, dose, comedication, response evaluation and safety. The document is aimed at supporting clinicians and informing patients, administrators and payers on opportunities and limitations of IL-6 pathway inhibition.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results